Fasting-mimicking diet blocks triple-negative breast cancer and cancer stem cell escape.
Level 5 - mechanism / opinion, no new human data
Preclinical cell and animal research with secondary human retrospective correlational data.
PubMed 34731655 · doi:10.1016/j.cmet.2021.10.008
What was done
Researchers investigated the effects of a fasting-mimicking diet (FMD) on triple-negative breast cancer (TNBC) cells and cancer stem cells (CSCs) in cell culture and mouse models. They examined downstream signaling pathways (protein kinase A, PI3K-AKT, mTOR, and CDK4/6), tested combinations of FMD with targeted pathway inhibitors, and evaluated survival associations with baseline glycemia in patients with metastatic TNBC.
What was found
The abstract reports directional findings without numerical values or effect sizes. In CSCs, FMD reduced glucose-dependent protein kinase A signaling and stemness markers, decreasing CSC counts and increasing mouse survival. In differentiated TNBC cells, FMD activated PI3K-AKT, mTOR, and CDK4/6 survival pathways, which when pharmacologically targeted led to tumor regression. FMD cycles also mitigated drug-induced hyperglycemia and toxicities. In clinical data, metastatic TNBC patients with lower baseline glycemia had longer survival than those with higher baseline glycemia.
Why it matters
This work outlines a translational framework where dietary fasting sensitizes TNBC tumors by simultaneously depleting cancer stem cells and exposing specific starvation escape pathways to targeted drug inhibition.
Limits
The abstract lacks quantitative effect sizes, confidence intervals, sample sizes for both animal cohorts and human patients, and detailed clinical characteristics. The human finding is correlational and observational, meaning clinical efficacy of FMD combinations in TNBC patients remains to be tested in controlled clinical trials.
Cited by
- supports In mammalian cells, glucose levels directly activate Protein Kinase A (PKA).